|
|
||||||||
European Journal of Cardio-Thoracic Surgery, Vol 6, 225-235, Copyright © 1992 by European Association for Cardio-thoracic Surgery
A Tschirkov, B Mishev, G Natschev, R Petkov, V Alexandrov and Z Jurukova
The effect of the calcium channel blocker, diltiazem, on cardiac
performance was examined in 90 patients who underwent isolated aortic valve
replacement for aortic valve diseases with marked left ventricular
hypertrophy. The patients were randomly assigned to one of five groups
dependent on the treatment plan with diltiazem: group 1, 5- day
preoperative treatment with oral administration of 60 mg diltiazem 3 times
daily, 10 mg diltiazem intravenously as a bolus dose before the beginning
of the cardiopulmonary bypass, and 5 mg diltiazem intravenously 10 min
before removal of aortic clamp; group 2, 5-day preoperative treatment with
oral administration of 60 mg diltiazem 3 times daily; group 3, 10 mg
diltiazem intravenously as a bolus dose before the beginning of CPB and 5
mg 10 min before removal of the aortic clamp; group 4, 15 mg diltiazem in
1000 ml cardioplegic solution, given as additive; group 5, control group
not receiving diltiazem. All operative procedures were performed in an
identical manner with an average cross-clamping time of 57.7 min and
cooling the heart down to 16 degrees-17 degrees septal temperature by
perfusion of the coronary arteries with 4 degrees C cold cardioplegic
solution. In each patient the heart rate (HR), cardiac output and cardiac
index (CO, CI), stroke volume index (SVI), left ventricular stroke work
index (LVSWI) and systemic vascular resistance index (SVRI) were recorded
and calculated before and after the ischemic period. Transmural samples
were obtained three times by needle biopsy technique from the anterior free
wall of the heart. Analysis of the variables revealed that: (1) complete
cessation of electromechanical activity was achieved significantly more
rapidly in groups 1 and 3 than in the other groups; (2) recovery of sinus
rhythm and function of the conductive system required significantly longer
in groups 1 and 3; (3) the time-related values of the important hemodynamic
factors (CO, CI, LWSVI and SVRI) showed a significantly more effective
postperfusion cardiac performance in groups 1 and 3 than in groups 2, 4 and
5. An oral dose of 180 mg diltiazem for 5 to 7 days preoperatively in
combination with intravenous administration of 10 mg before the beginning
of CPB and 5- 10 mg during reperfusion can be recommended in patients
undergoing open- heart surgery for isolated aortic valve diseases and left
ventricular hypertrophy.
ARTICLES
Perioperative myocardial protection with the calcium antagonist diltiazem
Department of Thoracic and Cardiovascular Surgery, Medical Academy, Sofia, Bulgaria.
This article has been cited by other articles:
![]() |
D. N. Wijeysundera, W. S. Beattie, V. Rao, and J. Karski Calcium antagonists reduce cardiovascular complications after cardiac surgery: A meta-analysis J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1496 - 1505. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |